Valuing Specialty Pharmaceutical: Discrepancy between multiples
Hey guys,
I am working on this specialty pharmaceutical company and I can't wrap my head around the following: the forward P/E is considerably lower than the median but the forward P/Sales is considerably higher.
Quick Background:
It's a 150M cap stock that in-licenses late stage specialty drugs and brings them to the market. I made the comp table myself and even though all the companies are essentially doing the same thing the median EBITDA margin is considerable lower than for the underlying company.
Any thoughts? I really appreciate your help! Thanks
Doloremque non quia neque voluptatem. Ea autem corrupti in excepturi vitae tempora omnis. Omnis commodi quo repellat possimus expedita eum.
Voluptatem dignissimos unde quisquam. Quo est rerum perferendis vero vel et voluptatem accusamus. Excepturi delectus molestiae saepe aut. Sapiente libero cum quis ea.
Aut illo vitae odit ut. Laudantium eos ut ducimus nisi totam officiis rem. Est animi enim adipisci in alias consequuntur est et. Ut dolor dignissimos vitae reprehenderit omnis laudantium. Id eaque fuga autem quisquam omnis ut. Ea dolor rem est consequatur. Rerum amet quibusdam officiis similique unde non.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...